Chicago, USA: April 25, 2025 -- Altis Labs, Inc. (“Altis”) is announcing results presented at the American Association for Cancer Research (AACR) 2025 in Chicago: in an advanced real world dataset, IPRO-Δ was able to predict overall survival 8 weeks post 1L systemic treatment initiation.
This study evaluated the ability of IPRO-Δ to predict overall survival (OS) in a cohort of 194 real world aNSCLC patients, including in patients with biomarker driven malignancies such as EGFR mutations. Kaplan-Meier analyses and hazard ratios evaluated association between IPRO-Δ survival score and OS. IPRO-Δ successfully predicted OS differences across the entire population using quartiles
These results demonstrate the ability of IPRO to provide early differentiation in OS amongst aNSCLC patients, and highlight IPRO’s potential feasibility to be a surrogate endpoint in clinical trials.
Access the abstract here.
About Altis Labs
Altis Labs is the computational imaging company accelerating clinical trials with AI.
Altis has created the industry's largest real-world Imaging, Clinical, and Outcomes database – comprising over 210 million cancer patient images linked to associated demographic, diagnostic, molecular, treatment, and survival information. Deep learning models trained on rwICO can generate profound insights beyond tumor measurements that make up reductionist criteria like RECIST 1.1, yielding greater association with overall survival.
Top 20 biopharma sponsors apply our deep learning models to their clinical trial imaging data to unlock powerful insights. Our models instantaneously generate Imaging-based Prognostication (IPRO) scores and thousands of Spatial Imaging Biomarkers (SIBs) from each scan, which Sponsors can combine for analysis with other data modalities such as ctDNA. These insights are being explored by clinical development teams to quantify treatment effects earlier in order to design more successful clinical trials.
Our multi-disciplinary team is on a mission to help get the most effective novel treatments to patients sooner. Altis is proudly headquartered in Toronto, Canada.
To learn more, email info@altislabs.com.